Close Menu

Febit is getting closer to settling a two-year-old legal dispute with Codon Devices over a patent that covers the manufacture of synthetic genes, and has decided to reevaluate its position in the competitive global synthetic-biology market.

"We don't want to be part of a commodity market with a lot of close competition," said Peer Stähler, Febit's chief scientific officer. "There are at least 20 companies worldwide that are competing to sell the cheapest genes."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Jan
26
Sponsored by
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.